ArticleThe Korean journal of pain2026
Aggrecan and small leucine-rich proteoglycan fragments correlate with Toll-like receptor-2 mediated inflammation in painful degenerative disc disease.
Article in The Korean journal of pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular matrix fragments and Toll-like receptor-2: reinforcing the mechanistic bridge from disc degeneration to inflammation in human tissue.The Korean journal of pain · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Painful intervertebral disc degeneration is a leading cause of chronic low back pain. Proteolytic cleavage fragments of extracellular matrix components, particularly aggrecan and small leucine-rich proteoglycans (SLRPs), may act as endogenous danger signals activating inflammatory pathways. To determine whether proteolytic fragments of aggrecan and SLRPs correlate with disc degeneration severity and Toll-like receptor-2 (TLR-2) mediated inflammation. Methods: Human disc tissues were analysed from 20 non-degenerated cadaveric controls (Thompson Grades 1-2) and 35 patients with painful degeneration (Pfirrmann Grades 3-5). Western blotting assessed fragmentation of aggrecan and SLRPs (decorin, biglycan, lumican, fibromodulin, chondroadherin). Immunofluorescence localized these molecules in disc sections. Disc cells were cultured under four conditions: unstimulated controls, TLR-2 agonist Pam2CSK4-stimulated controls, cells extracted from degenerated discs, and those treated with the TLR-2 antagonist MMG-11. Cytokine profiles were determined using antibody array. Results: Fragmented peptides of aggrecan and SLRPs (22-45 kDa) were predominantly detected in Pfirrmann Grades 4 and 5 discs. TLR-2 expression was significantly higher in degenerated disc cells versus controls ( Conclusions: Aggrecan and SLRP fragments were observed alongside TLR-2 mediated inflammatory responses in advanced disc degeneration, suggesting a potential association with tissue catabolism. Targeting TLR-2 signaling may warrant further investigations as a potential therapeutic strategy for painful disc disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.